Kymera Therapeutics, Inc. (NasdaqGM: KYMR)
Health Care · Biotechnology · US
$119.80
-1.40% today · +181.3% 1Y
Kymera Therapeutics, Inc. (NasdaqGM: KYMR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $9.96B and employs 273 people.
Over the last twelve months the share price has gained 181.3%, trading between 39.84 and 130.05.
Tweenvest scores Kymera Therapeutics, Inc. across four factors: quality 29/100, value 69/100, growth 0/100. Its strongest factor is value.
KYMR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.96B
- Revenue (TTM)
- $105.00M
- P/E
- —
- EPS
- -3.21
- Dividend yield
- —
- Beta (5Y)
- 1.95
- 52-week high
- $130.05
- 52-week low
- $39.84
- Avg volume (3M)
- —
- Shares outstanding
- 83.15M
- Employees
- 273
- Next earnings
- —
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
- Founded
- 2015
- Listed since
- Aug 21, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.